Shots:

• The companies enter into an agreement to evaluate the combination of Innovent's Tyvyt with Shenogen's SNG1005 for the patients with advanced cancer 
• Shenogen has in-licensed SNG1005 and has exclusive rights to develop & commercialize it in Greater China. SNG1005 has completed multiple P-II trials in the US with an approved NMPA’s IND application of P-II/III for breast cancer carcinoma brain metastases
• Tyvyt is an Ig-G4 mAb targeting PD-1- blocks PD-L1 pathway thus reactivates T-cells to kill cancer cells and has received NMPA’s approval for r/r cHL in Dec’18. SNG1005 is a first nab-paclitaxel therapeutic that binds to LRP1 and can penetrate the blood brain barrier

Click here to­ read full press release/ article

 Ref: PRNewswire | Image:Innovent